On June 8, 2024, the 3rd Qingcheng Breast Cancer Conference was successfully held in Chengdu. This conference was co-hosted by the Sichuan Provincial Women's Physicians Association, Sichuan Provincial Bioinformatics Society, and Chengdu Maternal and Child Health Society, and was undertaken by the Breast Disease Center of Sichuan Provincial People's Hospital. Academician Yang Zhenglin, President of Sichuan Provincial Medical Academy and Sichuan Provincial People's Hospital, Academician Chen Huiguang, President of Nanchang University, Professor Jiang Zefei from the General Hospital of the People's Liberation Army, Professor Wu Jing from Fudan University Cancer Hospital, Professor Liu Yinhua from the First Hospital of Peking University, Professor Ren Guosheng from the First Affiliated Hospital of Chongqing Medical University, and Professor Liu Jinping from Sichuan Provincial People's Hospital, along with more than a hundred top experts and renowned scholars in the field of breast diseases and related areas, gathered together to explore the frontiers of academic research on breast diseases, standardize the diagnosis and treatment of breast cancer, exchange clinical practice experience, and innovate in the prevention and treatment of breast diseases.

More than 300 industry experts from more than forty large public hospitals participated in this academic feast on-site, and more than 13,000 medical workers in the field of breast cancer learned through online live broadcast.

   Academician Yang Zhenglin mentioned in his opening speech: "Building the 'Qingcheng Breast Cancer Conference' as an academic exchange platform for breast diseases, with the aim of promoting the professional level of domestic breast disease studies, promoting standardized diagnosis and treatment of breast diseases, providing higher quality diagnostic and treatment services for patients, and providing lifelong breast health services for the people."

   Academician Chen Huiguang introduced several international cutting-edge research situations conducted by his team in his keynote report, among which a research result on breast cancer treatment was highly concerned. This research first revealed the direct regulation of TGF-β and HER2 signals at the receptor level, identifying the important function of HER2 S779 site phosphorylation for breast development and malignant transformation of breast cancer.

   Professor Jiang Zefei, when interpreting the "Chinese Clinical Oncology Society Breast Cancer Diagnosis and Treatment Guidelines 2024 Edition" released in April this year, said: "Precision classification and precise stratified treatment of breast cancer will help patients make reasonable resource allocation in the curable stage and the extended survival stage of the late stage, and good treatment needs to follow the guidelines, refer to consensus, combine experience, and respect wishes."

Professor Liu Yinhua interpreted the "Chinese Medical Association Breast Surgery Clinical Practice Guidelines" 2024 Edition, saying: "The diagnosis and treatment of breast tumors have changed from a one-size-fits-all approach to a must that both tumor cure and quality of life are equally important. The new guidelines reflect the latest research results in the field of breast cancer diagnosis and treatment, providing more comprehensive and precise treatment guidance for clinical doctors, and standardizing the clinical work of Chinese breast surgery."

Professor Wu Jing emphasized in his keynote report: "Improving the efficiency of specialty operations, promoting capacity training, strengthening high-efficiency collaboration among multiple disciplines, jointly improving the MDT surgical diagnosis and treatment ability and standardization, paying attention to evidence-based evidence and patient needs, formulating reasonable surgical treatment strategies, providing refined, comprehensive, humanistic, and palliative diagnostic and treatment experiences for patients, and meeting the needs of different patients are the future development directions of breast surgery."

   Professor Ren Guosheng mentioned: "This conference has both cutting-edge innovative research and also takes into account the needs of grassroots diagnosis and treatment. We hope to continue to strengthen cooperation and exchange in the future, promote the development of breast disease studies, benefit more patients, and let the voice of Chinese breast disease studies be heard in the world."

   Professor Liu Jinping said: "The Breast Disease Center of Sichuan Provincial People's Hospital has been committed to promoting the homogenization and standardization of diagnosis and treatment, and we hope that the Qingcheng Breast Cancer Conference can continue to make persistent efforts to help the high-quality development of breast disease diagnosis and treatment."

   Deputy Secretary-General Zhou Jiaoqiao of the Sichuan Provincial Bioinformatics Society pointed out in the sub-forum: "This forum has gathered top experts in the field of breast cancer diagnosis and treatment from inside and outside the province. They will conduct in-depth discussions on hot issues such as the pathogenesis of breast cancer, early diagnosis, precision treatment, and prognosis assessment. We look forward to strengthening academic exchange and cooperation through this conference to jointly promote the development of the field of breast cancer diagnosis and treatment."

The Qingcheng Breast Cancer Conference was established in May 2021, with the purpose of "exchange, innovation, collaboration, win-win". It has successfully held two sessions before, attracting more than a hundred top experts in the field of breast disease diagnosis and treatment for academic exchange. This Qingcheng Breast Cancer Conference was chaired by Academicians Yang Zhenglin, Jiang Zefei, Liu Yinhua, Wu Jing, Ren Guosheng, and Liu Jinping, and Professor Luo Jing of Sichuan Provincial People's Hospital served as the executive chairman of the conference. The conference set up seven forums including the main forum, high-end surgery forum, breast reconstruction forum, breast cancer diagnosis and treatment frontier speed forum, scientific research forum, nursing sub-venue, and breast tumor clinical practice challenge competition.

   Experts conducted nearly fifty keynote speeches and more than twenty high-end dialogues around more than ten professional academic directions such as early diagnosis and screening, precision diagnosis and treatment, targeted therapy, cutting-edge technology, surgical robot application, clinical surgery, guidelines interpretation, and patient management, bringing the front-line academic research dynamics of the breast field to the participants, sharing the latest diagnosis and treatment standards in the industry, and exchanging clinical practice experience and new ideas and new technologies for diagnosis and treatment. The cutting-edge and solid content made all the participants nod in praise from time to time, and they also took photos and notes from time to time.

   Professor Luo Jing said in the opening and summary: "The Qingcheng Breast Cancer Conference is built as a front-line academic exchange platform for breast tumors in China. We hope to promote further improvement of scientific research and clinical level of breast diseases in the Southwest region, as well as the homogenization development of breast specialties through this platform. We hope to further exchange and cooperate with domestic and foreign experts and colleagues in the field of breast tumor diagnosis and treatment in the future, to jointly promote the improvement of China's breast tumor diagnosis and treatment capabilities, and look forward to the next meeting." The Qingcheng Breast Cancer Conference has become a regular event, representing that another high-end academic brand conference in the field of breast disease diagnosis and treatment in China is gradually taking shape. The situation of breast cancer in our country is quite severe, but I believe that with similar academic exchange platforms such as the Qingcheng Breast Cancer Conference, which are "led by academic research and led by professional innovation", with the unremitting efforts of all medical staff and scientific researchers, our country's breast disease studies will make more significant progress and truly help to implement the Healthy China strategy.